Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is a strong potential investment due to its promising drug pipeline focusing on small-molecule precision medicines for neurological and psychiatric disorders. Their lead asset, RAP-219, has shown strong clinical evidence of efficacy in treating focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. There is a clear commercial opportunity for a well-tolerated, non-antipsychotic agent with even modest efficacy in the bipolar mania market. Additionally, their pipeline has potential for expansion into other indications, such as chronic pain and hearing disorders. With an estimated 30%-40% of patients with multi-drug refractory disease in the US, the potential market for Rapport's therapies is significant.

Bears say

Rapport Therapeutics is a clinical-stage biotechnology company with a negative outlook on its stock due to the high competition in the treatment of bipolar mania and the limited clinical evidence validating RAP-219's novel mechanism of action. While the drug has shown some promise in reducing seizures in epilepsy patients, its efficacy in treating bipolar mania is unproven and the company's Phase 2 trial results are not expected until 4Q26. Furthermore, Rapport's financials have not been publicly disclosed, making it difficult to assess the company's overall financial health.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.